MedPath

Investigation into Optimal Administration of Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid and Appropriate Timing of Arterial Phase of Enhanced Liver Magnetic Resonance Imaging for Hepatocellular Carcinoma

Not Applicable
Completed
Conditions
Hepatocellular carcinoma
Registration Number
JPRN-UMIN000004103
Lead Sponsor
Department of Radiology, Graduate School of Medicine, University of Tokyo
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
150
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with lesions that are received prior RFA or TAE treatment. 2) Patients with a history of hypersensitivity to gadolinium-based contrast agent or this test drug. 3) Patients who have asthma. 4) Patients with severe kidney disease. (eGFR<30mL/min/1.73square meter or serum Cr>1.5mg/dl) 5) Patients during pregnancy or potential pregnancy. 6) Patients who are lactating women. 7) Patients who have advanced nyctophobia cabin.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath